dapivirine has been researched along with nevirapine in 18 studies
| Studies (dapivirine) | Trials (dapivirine) | Recent Studies (post-2010) (dapivirine) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
|---|---|---|---|---|---|
| 196 | 64 | 160 | 3,212 | 509 | 1,108 |
| Protein | Taxonomy | dapivirine (IC50) | nevirapine (IC50) |
|---|---|---|---|
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
| Prothrombin | Bos taurus (cattle) | 1.15 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
| Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
| Protease | Human immunodeficiency virus 1 | 0.101 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Arnold, E; Azijn, H; Daeyaert, FF; Das, K; de Béthune, MP; De Corte, BL; de Jonge, MR; Heeres, J; Ho, CY; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Van Aken, KJ; Ye, H | 1 |
| Andries, K; Arnold, E; Boyer, PL; Clark, AD; Clark, P; Daeyaert, F; Das, K; De Béthune, MP; De Corte, B; De Jonge, MR; Heeres, J; Ho, CY; Hughes, SH; Janssen, PA; Kavash, RW; Koymans, LM; Kukla, MJ; Lewi, PJ; Lichtenstein, MA; Ludovici, DW; Pauwels, R; Vinkers, HM; Ye, H | 1 |
| De Corte, BL | 1 |
| Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P | 1 |
| Armanasco, N; Azijn, H; de Bethune, MP; Fletcher, P; Harman, S; Manlow, P; Nuttall, J; Perumal, D; Romano, J; Shattock, R | 1 |
| Bar-Magen, T; Brenner, BG; Oliveira, M; Quan, Y; Schader, SM; Wainberg, MA; Xu, H | 1 |
| Bar-Magen, T; Oliveira, M; Quan, Y; Schader, SM; Wainberg, MA; Xu, HT | 1 |
| Artico, M; Clotet, B; Esté, JA; Gonzalez-Ortega, E; Maga, G; Mai, A; Nawrozkij, MB; Rotili, D; Samuele, A; Tarantino, D | 1 |
| Artico, M; Ballante, F; Botta, G; Cirilli, R; Clotet, B; Esté, JA; Gonzalez, E; Maga, G; Mai, A; Morera, L; Musmuca, I; Nawrozkij, MB; Pierini, M; Ragno, R; Rotili, D; Samuele, A; Tarantino, D | 1 |
| Anderson, KS; Arnold, E; Bauman, JD; Bollini, M; Cisneros, JA; Das, K; Frey, KM; Jorgensen, WL; Spasov, KA | 1 |
| Anderson, KS; Bollini, M; Cisneros, JA; Jorgensen, WL; Spasov, KA | 1 |
| Collu, G; Giliberti, G; La Colla, P; Loddo, R; Loksha, YM; Pedersen, EB; Sanna, G | 1 |
| Ariën, KK; Augustyns, K; Cos, P; Dirié, B; Heeres, J; Joossens, J; Lewi, PJ; Lyssens, S; Maes, L; Michiels, J; Van der Veken, P; Vanham, G; Venkatraj, M | 1 |
| Ariën, KK; Bizzarri, BM; Botta, M; Brai, A; Canducci, F; Cascone, L; Casian, A; Ceresola, E; Crespan, E; Dasso Lang, MC; Deodato, D; Dreassi, E; Greco, AM; Maga, G; Tintori, C; Vanham, G; Zamperini, C | 1 |
| Jorgensen, WL | 1 |
| Armijos Rivera, JI; Badia, R; Cirilli, R; Crespan, E; Esté, JA; Forgione, M; Hailu, GS; Kirillov, IA; Lucidi, A; Maga, G; Mai, A; Nawrozkij, MB; Panella, C; Patsilinakos, A; Ragno, R; Riveira-Muñoz, E; Rotili, D; Tomaselli, D; Yablokov, AS | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT | 1 |
2 review(s) available for dapivirine and nevirapine
| Article | Year |
|---|---|
From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Benzodiazepines; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; Imidazoles; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2005 |
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine | 2005 |
16 other study(ies) available for dapivirine and nevirapine
| Article | Year |
|---|---|
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
Topics: Anti-HIV Agents; Drug Evaluation, Preclinical; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Mutation; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2001 |
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
Topics: Anti-HIV Agents; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; Models, Molecular; Mutation; Nitriles; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2004 |
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Luciferases; Macrophages; Organ Culture Techniques; Pyrimidines; Reverse Transcriptase Inhibitors; T-Lymphocytes | 2009 |
Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Mutation; Nitriles; Pyridazines; Pyrimidines; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2009 |
The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
Topics: Anti-HIV Agents; Base Sequence; Cell Line; DNA, Viral; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Recombinant Proteins; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
Topics: Anti-HIV Agents; HIV-1; Pyrimidines | 2011 |
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
Topics: Anti-HIV Agents; Benzene Derivatives; Cell Line; Enzyme Assays; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Models, Molecular; Mutation; Pyrimidinones; Stereoisomerism; Structure-Activity Relationship | 2012 |
Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
Topics: Anti-HIV Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Molecular Structure; Pyrimidines; Solubility; Structure-Activity Relationship | 2013 |
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Dose-Response Relationship, Drug; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Solubility; Structure-Activity Relationship | 2013 |
Synthesis of novel fluoro analogues of MKC442 as microbicides.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2014 |
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense | 2014 |
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.
Topics: Administration, Intravaginal; Anti-HIV Agents; Cell Survival; Chemistry, Pharmaceutical; DNA, Viral; Dose-Response Relationship, Drug; Drug Design; Gels; HIV-1; Models, Molecular; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors | 2016 |
Computer-aided discovery of anti-HIV agents.
Topics: Anti-HIV Agents; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes | 2016 |
Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Mutation; Protein Structure, Tertiary; Pyrimidinones; Stereoisomerism; Structure-Activity Relationship | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2013 |